CL2022001260A1 - Tratamiento del angioedema hereditario con vectores de terapia de genes específicos del hígado - Google Patents

Tratamiento del angioedema hereditario con vectores de terapia de genes específicos del hígado

Info

Publication number
CL2022001260A1
CL2022001260A1 CL2022001260A CL2022001260A CL2022001260A1 CL 2022001260 A1 CL2022001260 A1 CL 2022001260A1 CL 2022001260 A CL2022001260 A CL 2022001260A CL 2022001260 A CL2022001260 A CL 2022001260A CL 2022001260 A1 CL2022001260 A1 CL 2022001260A1
Authority
CL
Chile
Prior art keywords
liver
treatment
gene therapy
specific gene
therapy vectors
Prior art date
Application number
CL2022001260A
Other languages
English (en)
Inventor
Colosi Peter
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of CL2022001260A1 publication Critical patent/CL2022001260A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Aquí se proporcionan composiciones y métodos para tratar una deficiencia del inhibidor de la esterasa C1 normalizando los niveles de la proteína inhibidora de la esterasa C1 en un sujeto que tiene HAE.
CL2022001260A 2019-11-14 2022-05-13 Tratamiento del angioedema hereditario con vectores de terapia de genes específicos del hígado CL2022001260A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962935359P 2019-11-14 2019-11-14
US202063016365P 2020-04-28 2020-04-28

Publications (1)

Publication Number Publication Date
CL2022001260A1 true CL2022001260A1 (es) 2023-03-10

Family

ID=73834586

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001260A CL2022001260A1 (es) 2019-11-14 2022-05-13 Tratamiento del angioedema hereditario con vectores de terapia de genes específicos del hígado

Country Status (14)

Country Link
US (1) US20230340078A1 (es)
EP (1) EP4058475A1 (es)
JP (1) JP2023503850A (es)
KR (1) KR20220098210A (es)
CN (1) CN114829391A (es)
AU (1) AU2020384294A1 (es)
BR (1) BR112022009279A2 (es)
CA (1) CA3161154A1 (es)
CL (1) CL2022001260A1 (es)
CO (1) CO2022005641A2 (es)
IL (1) IL292717A (es)
MX (1) MX2022005869A (es)
TW (1) TW202128733A (es)
WO (1) WO2021097157A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230078805A (ko) 2020-11-02 2023-06-02 바이오마린 파머수티컬 인크. 아데노-연관 바이러스의 농축 공정
AU2022292164A1 (en) * 2021-06-17 2024-02-01 Meiragtx Uk Ii Limited Aav manufacturing methods
AR127217A1 (es) 2021-10-01 2023-12-27 Biomarin Pharm Inc Tratamiento de angioedema hereditario con vectores de genoterapia de aav y formulaciones terapéuticas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
WO2003033710A1 (fr) 2001-10-16 2003-04-24 National Institute Of Advanced Industrial Science And Technology Nouvelle n-acetylglucosamine transferase, acide nucleique codant cette enzyme, anticorps dirige contre cette enzyme et utilisation de l'enzyme pour diagnostiquer un cancer ou une tumeur
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
EP2338900B1 (en) 2001-11-13 2014-01-01 The Trustees of The University of Pennsylvania Adeno-associated virus (AAV) Cy.5 sequences, vectors containing the same and uses thereof
WO2003074714A1 (en) 2002-03-05 2003-09-12 Stichting Voor De Technische Wetenschappen Baculovirus expression system
US7943379B2 (en) 2008-04-30 2011-05-17 Nationwide Children's Hospital, Inc. Production of rAAV in vero cells using particular adenovirus helpers
RU2653444C2 (ru) 2012-02-17 2018-05-08 Дзе Чилдрен'З Хоспитал Оф Филадельфия Композиции вектора aav и способы переноса генов в клетки, органы и ткани
PE20160188A1 (es) * 2013-07-22 2016-04-27 Philadelphia Children Hospital Variantes aav y composiciones, metodos y usos para transferencia de gen a celulas, organos y tejidos
AU2016267687B2 (en) * 2015-05-28 2022-04-07 Cornell University Adeno-associated virus mediated delivery of C1EI as a therapy for angioedema
SG11201811603WA (en) 2016-07-26 2019-02-27 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
WO2019143272A1 (en) * 2018-01-16 2019-07-25 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (dnase) activity

Also Published As

Publication number Publication date
TW202128733A (zh) 2021-08-01
EP4058475A1 (en) 2022-09-21
CA3161154A1 (en) 2021-05-20
AU2020384294A1 (en) 2022-06-02
BR112022009279A2 (pt) 2022-09-06
JP2023503850A (ja) 2023-02-01
CO2022005641A2 (es) 2022-05-20
IL292717A (en) 2022-07-01
CN114829391A (zh) 2022-07-29
MX2022005869A (es) 2022-06-14
WO2021097157A1 (en) 2021-05-20
US20230340078A1 (en) 2023-10-26
KR20220098210A (ko) 2022-07-11

Similar Documents

Publication Publication Date Title
CL2022001260A1 (es) Tratamiento del angioedema hereditario con vectores de terapia de genes específicos del hígado
CY1124951T1 (el) Συνδυαστικη θεραπεια για την αντιμετωπιση των κακοηθειων
CL2018000955A1 (es) Terapia de combinación para el tratamiento de neoplasias malignas
MY194175A (en) Variant rnai
MX2018014256A (es) Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
BR112018007304A2 (pt) terapia de combinação para tratamento de malignidades
CO2022012196A2 (es) Composiciones y métodos para la edición de genes de calicreína (klkb1)
CL2021001552A1 (es) Moléculas inhibidoras de ácido nucleico de doble hebra que contienen un triloop
CL2022001256A1 (es) Métodos y composiciones para tratar un trastorno asociado con el angiotensinogeno agt
CL2021002262A1 (es) Composiciones y métodos para tratar laminopatías
CY1123489T1 (el) Μεθοδοι θεραπειας του καρκινου με ημιζυγωτικη απωλεια του tp53
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
MX2021013913A (es) Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
CO2020016718A2 (es) Terapia génica cardíaca con aav para cardiomiopatía
EA202092748A1 (ru) Модуляторы экспрессии apol1
CL2021001488A1 (es) Transposasa de piggybac mutada
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
AR121390A1 (es) Composiciones y métodos para tratar la deficiencia auditiva no relacionada con la edad en un sujeto humano
CO2022006367A2 (es) Tratamiento génico para la enfermedad de alzheimer
AR120461A1 (es) Tratamiento del angioedema hereditario con vectores de terapia de genes específicos del hígado
ZA202103975B (en) Methods of treating disease with magl inhibitors
EA202092487A1 (ru) Ферменты кинурениназы человека и их применение
MX2021008865A (es) Inhibidores de magl para usarse para tratar enfermedades antecedentes.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
BR112023020490A2 (pt) Composições e métodos para expressão de transgenes oculares